AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31969177 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenezumab
Number of subjects: 131
Study 31186524 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 28818049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 217
Study 28818049 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 217
Study 28818049 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 217
Study 27802555 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus OMT (OMT)
Number of subjects: 400
Study 27802555 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus placebo ultrasound treatment (PUT)
Number of subjects: 400
Study 27802555 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (UCO)
Number of subjects: 400
Study 24999798 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h average aortic SBP
Number of subjects: 229
Study 24999798 — intervention group
Group type: COMPARATOR
Intervention: 24-h average brachial SBP
Number of subjects: 229
Study 23097606 — intervention group
Group type: EXPERIMENTAL
Intervention: APP ON phases
Number of subjects: 50
Study 23097606 — intervention group
Group type: COMPARATOR
Intervention: APP OFF phases
Number of subjects: 50
Study 23097606 — intervention group
Group type: EXPERIMENTAL
Intervention: APP OFF and APP ON phases
Number of subjects: 50
Study 19596934 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (target dose, 100 mg daily)
Number of subjects: 114
Study 19596934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 17224708 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/d
Number of subjects: 50
Study 17224708 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/d
Number of subjects: 50
Study 17224708 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 600 mg/d
Number of subjects: 50
Study 17224708 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI category (normal-weight)
Number of subjects: 50
Study 17224708 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI category (overweight)
Number of subjects: 50
Study 17224708 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI category (obese)
Number of subjects: 50
Study 14694498 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation (5 g daily)
Number of subjects: 34
Study 14694498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11813077 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activities (walking)
Number of subjects: 89
Study 11813077 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health status
Number of subjects: 89
Study 11813077 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic diseases
Number of subjects: 89
Study 11813077 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 89
Study 11813077 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of death
Number of subjects: 89
Study 9825105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 60
Study 9825105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg orally once a day or 200 mg intravenously twice a day for 2‐4 days followed by oral use for 6‐8 days)
Number of subjects: 60
Study 9825105 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 60
Study 7621388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine alone
Number of subjects: 108
Study 7621388 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy alone
Number of subjects: 108
Study 7621388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine and behaviour therapy
Number of subjects: 108
Study 7621388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 2691256 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms folic acid (FA)/day
Number of subjects: 21
Study 2691256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 4577839 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 68
Study 4577839 — intervention group
Group type: COMPARATOR
Intervention: Gefarnate
Number of subjects: 68
Study 31934790 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive narrative
Number of subjects: 0
Study 31934790 — intervention group
Group type: COMPARATOR
Intervention: Traditional linear narrative
Number of subjects: 0
Study 31238631 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch and wait (W&W) strategy
Number of subjects: 0
Study 31238631 — intervention group
Group type: EXPERIMENTAL
Intervention: Total neoadjuvant therapy (TNT)
Number of subjects: 0
Study 31238631 — intervention group
Group type: COMPARATOR
Intervention: Watch and wait (W&W) strategy after cCR
Number of subjects: 0
Study 31238631 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery
Number of subjects: 0
Study 28348185 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fixation followed by mobilisation in a walking boot for 6 weeks
Number of subjects: 160
Study 28348185 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management in a walking boot for 6 weeks
Number of subjects: 160
Study 28348185 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group
Number of subjects: 160
Study 28348185 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical group
Number of subjects: 160
Study 25444803 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (3.75 μg antigen with half a standard dose of MF59)
Number of subjects: 354
Study 25444803 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (7.5 μg antigen with a full dose of MF59)
Number of subjects: 354
Study 25444803 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (15 μg formulation)
Number of subjects: 354
Study 25444803 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted vaccine (3.75 μg antigen)
Number of subjects: 354
Study 25444803 — intervention group
Group type: EXPERIMENTAL
Intervention: All A/H1N1 vaccine formulations
Number of subjects: 354
Study 22405535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 24
Study 22405535 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 24
Study 22405535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 24
Study 22063370 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (20mg)
Number of subjects: 55
Study 22063370 — intervention group
Group type: COMPARATOR
Intervention: Morphine (20mg)
Number of subjects: 55
Study 22063370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19691149 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based care management for 2 years by a nurse practitioner and social worker
Number of subjects: 951
Study 19691149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 951
Study 17005278 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) for AVMs
Number of subjects: 40
Study 17005278 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) for brain metastases
Number of subjects: 40
Study 17005278 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) for both AVMs and brain metastases
Number of subjects: 40
Study 12760628 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger task with progressively delayed onset of stimulus attribute
Number of subjects: 0
Study 12760628 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation of response sets of the tasks
Number of subjects: 0
Study 11296514 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-etched molar bands
Number of subjects: 79
Study 11296514 — intervention group
Group type: COMPARATOR
Intervention: Untreated molar bands
Number of subjects: 79
Study 9063787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft‐TC Red (cryopreserved to maintain fibroblast viability)
Number of subjects: 10
Study 9063787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft‐TC Blue (frozen without efforts to maintain fibroblast viability)
Number of subjects: 10
Study 9063787 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved human cadaver allograft skin (HCAS)
Number of subjects: 10
Study 8287640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoglycaemia (3.3 mmol/l)
Number of subjects: 11
Study 8287640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoglycaemia (3.7 mmol/l)
Number of subjects: 11
Study 8287640 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoglycaemia (2.5 mmol/l) after mild hypoglycaemia
Number of subjects: 11
Study 8287640 — intervention group
Group type: COMPARATOR
Intervention: Control (blood glucose maintained at 4.5 mmol/l)
Number of subjects: 11
Study 3458726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrices containing 0.5% zinc citrate (ZCT)
Number of subjects: 88
Study 3458726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrices containing 0.4% stannous fluoride
Number of subjects: 88
Study 3458726 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice
Number of subjects: 88
Study 30053162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 310
Study 30053162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 310
Study 30053162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially) then re-randomized to ixekizumab
Number of subjects: 310
Study 30053162 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall safety profile of ixekizumab
Number of subjects: 310
Study 27609106 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyethyl lysine
Number of subjects: 168
Study 27609106 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylglyoxal hydroimidazolone
Number of subjects: 168
Study 25110439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) administered at a dose of 3 ng/kg per min for 10 min intravenously before ESWL
Number of subjects: 148
Study 25110439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK)
Number of subjects: 148
Study 25110439 — intervention group
Group type: COMPARATOR
Intervention: No Cholecystokinin (no CCK)
Number of subjects: 148
Study 22273629 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 176
Study 20528836 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 15
Study 20528836 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 15
Study 20528836 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 15
Study 20528836 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 18809608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with the six-peptide melanoma vaccine
Number of subjects: 39
Study 16138265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg)
Number of subjects: 173
Study 16138265 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1-6 mg)
Number of subjects: 173
Study 12374234 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg)
Number of subjects: 31
Study 12374234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates (0.1 mg/kg)
Number of subjects: 31
Study 12374234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates plus Propranolol
Number of subjects: 31
Study 12374234 — intervention group
Group type: COMPARATOR
Intervention: Propranolol vs. Placebo (NaCl)
Number of subjects: 31
Study 10196647 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre (canalith repositioning manoeuvre)
Number of subjects: 41
Study 10196647 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 41
Study 7558945 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (two cycles of cisplatin 100 mg/m2 Day 1, 5-fluorouracil 1000 mg/m2 24-h infusion Days 2, 3, and 4 before radical radiotherapy, and four cycles of postradiotherapy chemotherapy)
Number of subjects: 82
Study 7558945 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 82
Study 7558945 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 82
Study 2130365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 21
Study 2130365 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (Control)
Number of subjects: 21
Study 855810 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of lysine with 260 mg of tryptophan
Number of subjects: 0
Study 855810 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of lysine with 390 mg of tryptophan
Number of subjects: 0
Study 855810 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of lysine with 520 mg of tryptophan
Number of subjects: 0
Study 855810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg of lysine with 260 mg of tryptophan
Number of subjects: 0
Study 855810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg of lysine with 390 mg of tryptophan
Number of subjects: 0
Study 855810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg of lysine with 520 mg of tryptophan
Number of subjects: 0
Study 30222478 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20
Study 27902493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amisulpride (5 mg)
Number of subjects: 689
Study 27902493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 689
Study 25467617 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 150
Study 25467617 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus insulin
Number of subjects: 150
Study 25467617 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 150
Study 25467617 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treated groups
Number of subjects: 150
Study 25467617 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin group
Number of subjects: 150
Study 23563442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys extended wear (EW)
Number of subjects: 47
Study 23563442 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily wear (DW)
Number of subjects: 47
Study 23563442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys extended wear (EW) after 1 month
Number of subjects: 47
Study 23563442 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys extended wear (EW) after the first night
Number of subjects: 47
Study 23563442 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL profile
Number of subjects: 47
Study 20837368 — intervention group
Group type: EXPERIMENTAL
Intervention: P wave wavelet analysis
Number of subjects: 50
Study 20837368 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals without history of PAF)
Number of subjects: 50
Study 18091330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesteatoma group
Number of subjects: 31
Study 18091330 — intervention group
Group type: COMPARATOR
Intervention: Normally hearing nonsyndromic controls
Number of subjects: 31
Study 17315796 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 27
Study 17315796 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Vitremer)
Number of subjects: 27
Study 15189587 — intervention group
Group type: EXPERIMENTAL
Intervention: Accusations made by individuals with faults
Number of subjects: 0
Study 15189587 — intervention group
Group type: COMPARATOR
Intervention: Accusations made by individuals with no faults
Number of subjects: 0
Study 11128173 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 181
Study 9362179 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 85
Study 9362179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 1560429 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, Methyldopa, Propranolol
Number of subjects: 620
Study 1560429 — intervention group
Group type: COMPARATOR
Intervention: One antihypertensive medication
Number of subjects: 620
Study 2865150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 90
Study 2865150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30698629 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiskimmed milk (1.5% fat) for 4 days
Number of subjects: 109
Study 30698629 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (3.5% fat) for 4 days
Number of subjects: 109
Study 30698629 — intervention group
Group type: COMPARATOR
Intervention: Control (wash-out periods)
Number of subjects: 109
Study 30137550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 116
Study 30137550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 116
Study 26861942 — intervention group
Group type: EXPERIMENTAL
Intervention: EQUIA, a new glass ionomer restoration material
Number of subjects: 323
Study 25012072 — intervention group
Group type: EXPERIMENTAL
Intervention: Single psycho‐oncological therapy session
Number of subjects: 45
Study 25012072 — intervention group
Group type: COMPARATOR
Intervention: Single‐session relaxation intervention
Number of subjects: 45
Study 25012072 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis of both interventions
Number of subjects: 45
Study 22450428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150-300 mg/daily)
Number of subjects: 50
Study 22450428 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5-10 mg/daily)
Number of subjects: 50
Study 20116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Single gloves
Number of subjects: 1537
Study 20116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves (outer glove)
Number of subjects: 1537
Study 20116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves (inner glove)
Number of subjects: 1537
Study 20116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons
Number of subjects: 1537
Study 20116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 1537
Study 20116312 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistants
Number of subjects: 1537
Study 17139035 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy for 1 year
Number of subjects: 0
Study 17139035 — intervention group
Group type: COMPARATOR
Intervention: Lithium monotherapy for 1 year
Number of subjects: 0
Study 17139035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psychotic features
Number of subjects: 0
Study 17139035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a greater number of previous depressive episodes
Number of subjects: 0
Study 15107915 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide‐eugenol cement
Number of subjects: 60
Study 15107915 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 60
Study 10958077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cocaine (100 mg, p.o.)
Number of subjects: 8
Study 10958077 — intervention group
Group type: COMPARATOR
Intervention: Oral cocaine (0 mg, 25 mg, 50 mg, 100 mg, 0 mg)
Number of subjects: 8
Study 9078828 — intervention group
Group type: EXPERIMENTAL
Intervention: Early indomethacin (0.2 mg/kg intravenously at 12 postnatal hours and every 24 h for two more doses)
Number of subjects: 27
Study 9078828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8384820 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha 2B interferon
Number of subjects: 24
Study 3267404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training on spatial orientation
Number of subjects: 0
Study 3267404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training on inductive reasoning
Number of subjects: 0
Study 3267404 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training interventions
Number of subjects: 0
Study 31752795 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drinks consumption
Number of subjects: 783
Study 31752795 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of energy drinks
Number of subjects: 783
Study 31752795 — intervention group
Group type: COMPARATOR
Intervention: Energy drinks consumption frequency
Number of subjects: 783
Study 29595671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (2.0 mg/kg bolus, 3.0 mg/kg/h infusion)
Number of subjects: 40
Study 29595671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 40
Study 29595671 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study 26551637 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) as consolidation treatment in first remission for HR(FLT3‐ITD) AML
Number of subjects: 209
Study 26551637 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) in first remission for LR(FLT3‐ITD) AML and wild-type NPM1
Number of subjects: 209
Study 26551637 — intervention group
Group type: COMPARATOR
Intervention: Consolidation chemotherapy for HR(FLT3‐ITD) AML
Number of subjects: 209
Study 26551637 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) in first remission for LR(FLT3‐ITD) AML with concomitant NPM1 mutation
Number of subjects: 209
Study 25042700 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic FOLFOXIRI)
Number of subjects: 17
Study 25042700 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (FOLFOXIRI alone)
Number of subjects: 17
Study 22500909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium (0.5 mL magnesium 10% combined with bupivacaine 15 mg)
Number of subjects: 90